How Does Direct Meds Work In 2026
[Saxenda] is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva's diverse complex generics portfolio" Ernie Richardsen, Head of US Commercial Generics at Teva, said: This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva's diverse complex generics portfolio. Approval of the GLP-1 will see Teva compete with Novos obesity drug Wegovy (semaglutide), which it markets as Ozempic to treat diabetes, and Lillys Zepbound (tirzepatide)
Ipamorelin's structure emerged from a different optimization strategyremoval of the central dipeptide from GHRP-1 combined with Aib N-terminal substitutionresulting in a pentapeptide with potency comparable to hexapeptide GHRPs but with fundamentally different selectivity
If the advisory panel votes against reclassification, or if a future administration revisits the question, these compounds could return to Category 2 restriction
Naturally increases GLP-1 (glucagon-like peptide-1) hormone levels to reduce appetite, suppress cravings, and balance blood sugar levels